China healthcare: greying population, golden opportunity

China's healthcare sector is being driven by China's rapidly expanding aged population.

by China Equities team 15 fev 2018

China healthcare: greying population, golden opportunity – in 60 seconds

  • China's aging population means 115 million more people aged 65+ by 2030, according to the United Nations;
  • China's healthcare system will face many more cases of age-associated conditions and chronic disease as China's population ages;
  • China's healthcare sector and system will benefit as public and private healthcare spending grows;
  • Chinese healthcare companies are increasing R&D spending to develop innovative pharmaceutical drugs and treatments;
  • We see good growth prospects in China's healthcare sector and we are focusing on the most innovative companies with the best long-term prospects

China's elderly population: how quickly is it growing?

With more than six times the total in Japan and three times that in the US, China's estimated population of 245.9 million people aged 65+ in 2030 will be the world's largest, according to UN forecasts (1).

While the 65+ population will be huge in 2030, it will get there at a rapid rate. 115 million more people will be aged over 65 in China by 2030, and that means annual growth of 4.2%, almost double the 2.3% rate recorded between 2000 and 2015.

115 million more people will be aged over 65 in China by 2030

How will China's aged population compare with other countries by 2030

Source: United Nations Population Division: World Population Prospects 2017.

How is China's aging population affecting the healthcare sector?

This rapid growth and the sheer size of the 65+ demographic means more cases of age-associated conditions, such as mobility, vision, and hearing impairment, plus a greater number of chronic disease cases, such as diabetes and hypertension, according to the World Health Organization (2)

Taking diabetes as an example, 150.6 million Chinese are expected to have it by 2040, a 37% increase on 2015, and total expenditure on care and treatments will reach an estimated USD 71.8 billion, up from USD 51 billion in 2015, according to estimates by the International Diabetes Federation (3).

Is healthcare spending growing in China?

China's government is stepping up investment in healthcare services, with total spending increasing by a factor of five between 2004 and 2014 (4), according to World Health Organization (WHO) data (4), as it has built facilities and increased the supply of medical services.

A further source of demand for healthcare comes from Chinese citizens' increasing spending on medical services. As incomes rise and healthcare options increase, consumers are spending more on private healthcare, with total private spending growing an estimated 16.4% per year between 2005 and 2014, according to WHO data (4).

And while the rates of both public and private health expenditure are growing fast, there is still significant room for growth because actual healthcare spending levels in China remain low by international standards, with healthcare spending in estimated at 5.5% of GDP in 2014, compared with 10.2% in Japan, and 17.1% in the US, according to WHO data.

Watch Bin Shi talk about China's healthcare sector here

How are Chinese healthcare companies responding to China's aging population?

While underlying macro trends are positive for the healthcare sector as a whole, competition is fierce, and that means Chinese companies have to innovate to take a share of the market.

Indeed, because of the size of the opportunity, and competition for sales, Chinese companies are boosting their R&D investments to create innovative products.

Chinese companies are innovating. Fast.

And this is creating a boom in new and innovative drug patents being produced by Chinese companies.

In 2015, Chinese firms registered 855 new pharmaceutical patents (5), up 151.4% compared with 2007 and outstripping growth in other global markets.

With recent reforms to speed up patent approval processes, we are expecting a strong pipeline of innovative products in the future.

What does China's aging population mean for investors in the healthcare sector?

So, with China's growing aged population, plus increasing spending on medical services, the long-term outlook looks strong for China's healthcare sector.

But innovation will be key, since competition is ratcheting up, and only companies with a strong innovative culture will be best set to capitalize on the undoubted opportunities in the sector.

Read more


Equity investments from a global player

Important legal information

To proceed, please confirm that you are a professional / qualified / institutional client and investor.

Views and opinions expressed are presented for informational purposes only and are a reflection of UBS Asset Management’s best judgment at the time a report or other content was compiled. UBS specifically prohibits the redistribution or reproduction of this material in whole or in part without the prior written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. The information and opinions contained in the content of this webpage have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any errors or omissions. All such information and opinions are subject to change without notice but any obligation to update or alter forward-looking statement as a result of new information, future events, or otherwise is disclaimed. Source for all data/charts, if not stated otherwise: UBS Asset Management.
Any market or investment views expressed are not intended to be investment research. Materials have not been prepared to address requirements designed to promote the independence of investment research and are not subject to any prohibition on dealing ahead of the dissemination of investment research. The information contained in this webpage does not constitute a distribution, nor should it be considered a recommendation to purchase or sell any particular security or fund. The materials and content provided will not constitute investment advice and should not be relied upon as the basis for investment decisions. As individual situations may differ, clients should seek independent professional tax, legal, accounting or other specialist advisors as to the legal and tax implication of investing. Plan fiduciaries should determine whether an investment program is prudent in light of a plan's own circumstances and overall portfolio. A number of the comments in the content of this webpage are considered forward-looking statements. Actual future results, however, may vary materially. Past performance is no guarantee of future results. Potential for profit is accompanied by possibility of loss. 
© UBS 2021 The key symbol and UBS are among the registered and unregistered trademarks of UBS.